Search Results - "Mozo, J.L. Manzano"

378P Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study by Vidal Barrull, J., Nieva Munoz, M., Fernandez-Rodriguez, C., García Alfonso, P., Paez, D., Alonso-Orduna, V., Cano Osuna, M.T., Santos Vivas, C., Duran, G., Elez Fernandez, M.E., Manzano Mozo, J.L., Garcia-Carbonero, R., Pineda, E., Sastre Varela, J., Rivera Herrero, F., Bellosillo Paricio, B., Tabernero, J., Aranda Aguilar, E., Salazar, R., Montagut Viladot, C.

Get full text

848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801 by Marquez-Rodas, I., Berciano Guerrero, M.A., Muñoz Couselo, E., Soria, A., Cerezuela-Fuentes, P., Manzano Mozo, J.L., Gutierrez Sanz, L., Crespo, G., Puértolas, T., Garcia Castano, A., Aguado de la Rosa, C., Espinosa, E., Majem Tarruella, M., López Castro, R., Ayala de Miguel, P., Medina Martinez, J., Fernández Morales, L.A., Bellido Hernández, L., Berrocal, A., Martín Algarra, S.

Get full text

811P Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901 - DESCRIBE-AD) by Cerezuela-Fuentes, P., Martín-Liberal, J., Fernández-Morales, L.A., Benítez, G., Medina Martinez, J., Quindós, M., García Castaño, A., Puértolas, T., Vilchez Simo, R., Fernández, O., Majem, M., Bellido Hernández, L., Ayala de Miguel, P., Campos, B., Espinosa, E., Macías Cerrolaza, J.A., Rodríguez-Lescure, A., Espasa Font, L., Belaustegui Ferrández, G., Manzano Mozo, J.L.

Get full text

1118P Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients by García-Castaño, A., González-Barrallo, I., Rubio, V.E. Castellón, Martínez, J. Medina, Mozo, J.L. Manzano, Mujika, K., Tarruella, M. Majem, Aguado de La Rosa, C., Suárez, M.A. Cabrera, Palacio, I., Osterloh, L., Fernandez, A. Martinez

Get full text

Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC) by Portales, F., Philip, P.A., Hammel, P., Buscaglia, M., Pazo-Cid, R., Manzano Mozo, J.L., Kim, E.S., Dowden, S., Zakari, A., Borg, C., Terrebonne, E., Rivera Herrero, F., Shiansong Li, J., Ong, T.J., Nydam, T., Lacy, J.

Get full text

nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial by Philip, P.A., Lacy, J., Portales, F., Sobrero, A., Pazo-Cid, R., Manzano Mozo, J.L., Kim, E.S., Dowden, S., Zakari, A., Borg, C., Terrebonne, E., Rivera Herrero, F., Shiansong Li, J., Ong, T.J., Nydam, T., Hammel, P.

Get full text

Safety and efficacy of encorafenib–cetuximab combination in BRAF-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study by Fernández-Montes, A., Ros, J., García-Alfonso, P., Graña, B., Brozos-Vázquez, E., Melián, M., Jiménez-Gordo, A.Mª, Martínez de Castro, E., Busquier, I., Ferrández Arias, A., Grávalos, C., Covela, M., Ruíz-Casado, A., González-Flores, E., Safont, Mª J., Cano, J.Mª, Alonso-López, C., Gómez-Reina, Mª J., Donnay, O., Manzano-Mozo, J.L., Sampedro Domarco, P., Falcó, E., Rodríguez, N., García-Benito, C., Aranda, E.

Get full text

Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group by Benavides, M., Carrato, A., Abad, A., Guillen-Ponce, C., Garcia-Alfonso, P., Gil, S., Cano Osuna, M.T., Safont, M.J., Gravalos, C., Manzano-Mozo, J.L., Sanchez, A., Alcaide-Garcia, J., López, R., Massuti Sureda, B., Sastre, J., Martinez de Castro, E., Escudero, P., Méndez-Ureña, M., Diaz Rubio, E., Aranda Aguilar, E.

Get full text

YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD) by Cubillo Gracian, A., Dean, A., Muñoz, A., Hidalgo, M., Pazo-Cid, R., Martin, M., Macarulla Mercade, T., Lipton, L., Harris, M., Manzano-Mozo, J.L., Maurel, J., Guillen-Ponce, C., Tebbutt, N., Cooray, P., Sohal, D., Zalupski, M., Kolevska, T., Stagg, R., Goldstein, D.

Get full text